Health Care Distributors

WANJIA GROUP

WANJIA GROUP released FY2026 Semi-Annual earnings on November 25 During-Market BJT, actual revenue HKD 85.71 M, actual EPS HKD -0.0012

WANJIA GROUP released FY2026 Q1 earnings on November 19, 2025 (BJT) with actual revenue of HKD 42.85 M and EPS of HKD -0.0006

WANJIA GROUP released FY2026 Q2 earnings on November 19 During-Market (BJT), actual revenue HKD 42.85 M, actual EPS HKD -0.0006

WANJIA GROUP to Release FY2026 Semi-Annual Earnings on November 19, 2025 (BJT)

WANJIA GROUP released FY2025 9 Months Earnings on June 20, 2025 (BJT) with actual revenue of HKD 122.69 M and EPS of HKD -0.0047

WANJIA GROUP released FY2025 Q3 earnings on June 20, 2025 (BJT), with actual revenue of HKD 39 M and EPS of HKD -0.007

WANJIA GROUP released FY2025 Annual Earnings on June 20 After-Market BJT, actual revenue HKD 161.69 M, actual EPS HKD -0.0118

WANJIA GROUP released FY2025 Q4 earnings on June 20 After-Market (BJT), actual revenue HKD 39 M, actual EPS HKD -0.007

Wan Jia Group Announces 2025 Annual Results

Wanji Group's Losses Significantly Reduced

Wanji Group Announces 86% Decrease in Expected Loss for FY2025 and Makes Refunds

WANJIA GROUP FY2025 Annual Earnings Release on June 20 After-Market BJT

WANJIA GROUP released FY2025 Q2 earnings on November 25 (BJT), with actual revenue of 41.85 M HKD and EPS of 0.0011 HKD

WANJIA GROUP released FY2025 Q1 earnings on November 25 (BJT), actual revenue 41.85 M HKD, actual EPS 0.0011 HKD

WANJIA GROUP released FY2025 H1 earnings on November 25, 2024 (BJT) with actual revenue of 83.695 M HKD and EPS of 0.0022

Wanjia Group's H1 2024 Performance Report: Revenue Decreased by 10.36%, Profit of HKD 1.256 Million

WANJIA GROUP to Release FY2025 Q2 Earnings on November 25, 2024 (BJT)

Wanjia Group Expects Profit Improvement

Wanjia Group (00401.HK) Stock Price Rises

WANJIA GROUP released FY2024 Annual Earnings on June 21, 2024 (BJT) with actual revenue of HKD 181.09 M and EPS of HKD -0.0713

I.CENTURY HLDG

RIVERINE CHINA

KOS TALENT GP

CHINA CBS INTL

NATURE ENERGY T

DIGIT HOLLYWOOD

REDCO HEALTHY

ZXZN QI-HOUSE

ASIA PIONEER

HUISHENG INTL

00401

WANJIA GROUP announced a proposed one-for-one rights issue, issuing at least 560 million shares; the rights issue price is HKD 0.08, representing a discount of 31.62% compared to the last trading day (30th). The net proceeds are not less than HKD 40.82 million, intended for the development of existing pharmaceutical wholesale and distribution business, as well as blood dialysis treatment and consulting services business and potential investment opportunities; repayment of amounts owed to a director; and general working capital

AASTOCKS

WANJIA GROUP offers a rights issue at a discount of 31.62%, raising at least HKD 40.82 million

Wanjia Group Holdings Ltd. plans to double its authorized share capital from HK$50 million to HK$100 million, pending shareholder approval. The company will also launch a rights issue of one new share for every existing share at HK$0.08 per share, aiming to raise approximately HK$40.82 million to HK$47.28 million. This move is intended to strengthen the company's capital base and provide funding flexibility, though it may lead to equity dilution for existing shareholders. The current analyst rating for the stock is a Hold with a price target of HK$0.14.

Tip Ranks

Wanjia Group to Double Authorised Share Capital and Launch HK$40–47 Million Rights Issue

Wanjia Group Holdings Limited's shares have dropped 27% in the past month, despite a 116% gain over the past year. The company's low price-to-sales ratio of 0.4x, compared to the industry average above 1x, reflects its declining revenue, which fell 4.5% last year and 6.3% over three years. This decline contrasts with the industry's expected 9.2% growth, suggesting potential future challenges for the stock's valuation.

Simplywall

Little Excitement Around Wanjia Group Holdings Limited's (HKG:401) Revenues As Shares Take 27% Pounding

Wanjia Group Holdings Ltd. reported revenue growth driven by its Hemodialysis Business for the six months ended September 30, 2025. Despite this, the company faced an operational loss of HK$0.712 million, with no interim dividend declared, highlighting financial challenges. The company is listed on the Hong Kong Stock Exchange and focuses on healthcare, specifically Hemodialysis.

Wanjia Group Holdings Reports Revenue Growth but Faces Operational Loss

Wanjia Group Holdings Ltd. (HK:0401) will hold a Board meeting on November 19, 2025, to review its unaudited interim results for the six months ending September 30, 2025, and discuss the payment of an interim dividend. This meeting is crucial for determining the company's financial direction and may affect shareholder returns and market perception. The current market cap is HK$81.23M with an average trading volume of 633,297 and a technical sentiment signal indicating a 'Buy'.

Wanjia Group Holdings to Review Interim Results and Dividend

WANJIA GROUP announced that its indirectly non-wholly-owned subsidiary Wuhua Yangke received a notice of agreement processing from the Wuhua Medical Insurance Management Center, stating that its dialysis center deviated from standard prescriptions and violated relevant regulations. The Wuhua Medical Insurance Management Center requires Wuhua Yangke to rectify the situation and has suspended its service agreement for 61 days. During the suspension period, the Wuhua dialysis center will continue to operate but will not provide dialysis services and will transfer patients to other centers. The company will take measures to ensure compliance and believes that the suspension will not have a significant impact on its financial condition

Zhitong

WANJIA GROUP: Wuhua Yang can receive the notice of agreement processing issued by the Wuhua Medical Insurance Management Center